Allogeneic Hematopoietic Cell Transplantation clinical trials at UC Irvine

2 research studies open to eligible people

Showing trials for

  • CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCT

    open to eligible people ages 18 years and up

    This is a phase 2, prospective cohort clinical trial evaluating the utilization of CMV T Cell Immunity Panel (CMV-TCIP) assay to guide the duration of primary CMV prophylaxis in CMV-seropositive recipients of allogeneic stem cell transplant or recipients receiving a stem cell graft from a CMV serology positive donor.

    Orange 5379513, California 5332921

  • Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

    open to eligible people ages 18-70

    This is a prospective, single-arm, phase II study. Patients will be treated with an allogeneic stem cell transplantation (AHSCT) using fludarabine, melphalan and total body irradiation (TBI) conditioning with different melphalan and TBI doses based on patient- and disease-related risk.

    Orange 5379513, California 5332921

Our lead scientists for Allogeneic Hematopoietic Cell Transplantation research studies include .

Last updated: